Seeing Is Believing

Currently out of the existing stock ratings of Thomas Shrader, 140 are a BUY (88.61%), 16 are a HOLD (10.13%), 2 are a SELL (1.27%).
Analyst Thomas Shrader, currently employed at BTIG, carries an average stock price target met ratio of 55.69% that have a potential upside of 49.87% achieved within 271 days.
Thomas Shrader’s has documented 296 price targets and ratings displayed on 45 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ARCT, Arcturus Therapeutics Holdings at 21-Oct-2025.
Analyst best performing recommendations are on VRNA (VERONA PHARMA PLC ADR).
The best stock recommendation documented was for VRNA (VERONA PHARMA PLC ADR) at 12/20/2022. The price target of $26 was fulfilled within 10 days with a profit of $7.41 (39.86%) receiving and performance score of 39.86.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$70
$15.74 (29.01%)
$70
1 months 16 days ago
(14-Sep-2025)
23/29 (79.31%)
$18.53 (36.00%)
301
Buy
$82
$27.74 (51.12%)
$72
1 months 19 days ago
(11-Sep-2025)
4/8 (50%)
$30.79 (60.12%)
342
Buy
$70
$15.74 (29.01%)
$50
1 months 28 days ago
(02-Sep-2025)
13/15 (86.67%)
$18.16 (35.03%)
176
Buy
$61
$6.74 (12.42%)
$60
2 months 25 days ago
(05-Aug-2025)
0/2 (0%)
$16.19 (36.13%)
Buy
$57
$2.74 (5.05%)
$55
2 months 25 days ago
(05-Aug-2025)
9/10 (90%)
$12.19 (27.20%)
213
Which stock is Thomas Shrader is most bullish on?
Which stock is Thomas Shrader is most reserved on?
What Year was the first public recommendation made by Thomas Shrader?